BIO-key Narrows Q2 Loss on Hardware Surge, Cash Up from Warrants

TL;DR

**BKYI's Q2 loss narrowed and cash jumped from warrant exercises, but the long-term viability is still a coin flip given persistent going concern warnings and declining six-month license revenue.**

AI Summary

BIO-KEY INTERNATIONAL INC (BKYI) reported a net loss of $1,167,396 for the three months ended June 30, 2025, a significant improvement from the $1,666,950 net loss in the prior-year period. Total revenues increased by 48.7% to $1,696,907 for the quarter, up from $1,141,286 in Q2 2024, driven primarily by a substantial increase in hardware revenue to $568,824 from $83,492. License fees also saw a modest increase to $806,087 from $774,225. However, for the six months ended June 30, 2025, total revenues slightly decreased to $3,304,066 from $3,322,489 in the same period last year, largely due to a decline in license fees from $2,724,659 to $1,904,845. The company's cash and cash equivalents surged to $2,275,344 as of June 30, 2025, from $437,604 at December 31, 2024, primarily due to $3,813,057 in proceeds from warrant exercises. Despite improved quarterly performance, the company continues to face a going concern risk due to historical significant losses and negative cash flow from operations, necessitating additional financing.

Why It Matters

BIO-key's ability to significantly reduce its quarterly net loss and boost cash reserves through warrant exercises is a critical, albeit temporary, lifeline for investors. The substantial increase in hardware revenue, particularly in the EMESA region, suggests potential market traction, but the overall six-month revenue decline in license fees raises questions about the sustainability of its core biometric software business. For employees, the going concern warning indicates continued job insecurity. Customers might see improved product availability due to increased hardware sales, but the company's financial instability could impact long-term support. Competitively, BIO-key operates in a crowded identity access management market, and its reliance on external financing for survival puts it at a disadvantage against more financially robust players.

Risk Assessment

Risk Level: high — The company explicitly states a 'substantial doubt about the Company's ability to continue as a going concern' due to 'history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability, to obtain additional financing.' This is further evidenced by an accumulated deficit of $131,211,843 as of June 30, 2025, and net cash used in operating activities of $1,715,324 for the six months ended June 30, 2025.

Analyst Insight

Investors should approach BKYI with extreme caution, recognizing the high going concern risk. While the increase in cash from warrant exercises provides short-term liquidity, the underlying business profitability remains a significant challenge. Monitor future filings closely for sustained revenue growth, especially in license fees, and a clear path to operational profitability before considering any investment.

Financial Highlights

debt To Equity

0.54

revenue

$3.30M

operating Margin

N/A

total Assets

$10.52M

total Debt

$3.66M

net Income

-$2.84M

eps

-$0.20

gross Margin

77.5%

cash Position

$2.28M

revenue Growth

-0.55%

Revenue Breakdown

Key Numbers

• $1.70M — Total revenues (Q2 2025) (Increased 48.7% from $1.14M in Q2 2024)
• $1.17M — Net loss (Q2 2025) (Improved from $1.67M net loss in Q2 2024)
• $2.28M — Cash and cash equivalents (June 30, 2025) (Increased from $0.44M at Dec 31, 2024)
• $3.81M — Proceeds from warrant exercises (YTD June 2025) (Significant source of cash inflow)
• $131.21M — Accumulated deficit (June 30, 2025) (Indicates historical losses and going concern risk)
• $1.72M — Net cash used in operating activities (YTD June 2025) (Continued negative operational cash flow)
• $568.8K — Hardware revenue (Q2 2025) (Increased from $83.5K in Q2 2024, a 583% jump)
• $1.90M — License fees (YTD June 2025) (Decreased from $2.72M in YTD June 2024)
• 6,863,776 — Common Stock Shares Outstanding (August 12, 2025) (Increased from 3,715,483 at Dec 31, 2024 due to warrant exercises and debt repayment)
• $0.20 — Basic and diluted loss per common share (Q2 2025) (Improved from $1.00 in Q2 2024)

Key Players & Entities

• BIO-KEY INTERNATIONAL INC (company) — Registrant as Specified in Its Charter
• Nasdaq Capital Market (regulator) — exchange where Common Stock is registered
• SEC (regulator) — Securities and Exchange Commission
• BBVA Bank (company) — provider of government loan
• $1,696,907 (dollar_amount) — Total revenues for three months ended June 30, 2025
• $1,167,396 (dollar_amount) — Net loss for three months ended June 30, 2025
• $2,275,344 (dollar_amount) — Cash and cash equivalents as of June 30, 2025
• $3,813,057 (dollar_amount) — Proceeds from exercise of warrants for six months ended June 30, 2025
• $131,211,843 (dollar_amount) — Accumulated deficit as of June 30, 2025
• $1,715,324 (dollar_amount) — Net cash used in operating activities for six months ended June 30, 2025

FAQ

Risk Factors

• Going Concern Risk [high — financial]: The company has a history of significant losses and negative cash flow from operations, resulting in an accumulated deficit of $131.21 million as of June 30, 2025. This raises substantial doubt about its ability to continue as a going concern, necessitating future financing.
• Dependence on Future Financing [high — financial]: The company's ability to fund its operations and strategic initiatives is contingent upon its success in obtaining additional financing. The proceeds from warrant exercises ($3.81 million year-to-date) have bolstered cash, but ongoing operational losses require sustained capital infusion.
• Revenue Volatility and Mix Shift [medium — operational]: While Q2 2025 saw a strong revenue increase driven by hardware, year-to-date revenues slightly decreased due to a significant drop in license fees ($1.90M vs $2.72M). This revenue mix shift and overall revenue decline for the six months indicate potential instability in revenue streams.
• Competition in Biometric Solutions [medium — market]: The biometric technology market is competitive. While not explicitly detailed in this 10-Q excerpt, the company's success depends on its ability to innovate and maintain market share against established and emerging players.
• Inventory Management [low — financial]: Inventory levels decreased from $378,307 at December 31, 2024, to $318,538 at June 30, 2025. While this could indicate efficient sales, it also requires careful management to meet demand, especially with the surge in hardware revenue.

Industry Context

BIO-KEY INTERNATIONAL INC operates in the biometric security and identity solutions market. This sector is characterized by rapid technological advancements, increasing demand for secure authentication across various industries (consumer electronics, enterprise, government), and a competitive landscape with both established players and emerging innovators. Trends include the shift towards multi-factor authentication and the integration of biometrics into broader identity management platforms.

Regulatory Implications

As a publicly traded company, BIO-KEY INTERNATIONAL INC is subject to SEC regulations and reporting requirements, including the need to disclose material risks such as going concern issues. Compliance with data privacy regulations (e.g., GDPR, CCPA) is also critical, given the sensitive nature of biometric data handled by its solutions.

What Investors Should Do

1. Monitor revenue diversification and sustainability.
2. Evaluate the company's ability to secure future funding.
3. Assess the impact of the 'Cost of hardware - reserve' adjustment.
4. Track the progress in addressing going concern risks.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported improved quarterly net loss and significant revenue growth, primarily driven by hardware sales. Cash position strengthened due to warrant exercises.
• 2025-06-30: End of H1 2025 — Total revenues slightly decreased year-over-year, impacted by a decline in license fees. Net cash used in operations remained negative.
• 2025-06-30: Balance Sheet Date — Cash and cash equivalents increased substantially to $2.28M from $0.44M at year-end 2024. Accumulated deficit stands at $131.21M.
• 2024-12-31: End of Fiscal Year 2024 — Reported cash and cash equivalents of $0.44M and an accumulated deficit of $129.31M, highlighting the need for improved financial performance and cash generation.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception, minus any net profits. It represents a negative retained earnings balance. (Indicates the company's historical unprofitability and contributes to the going concern risk.)

Warrant exercises

The process by which holders of stock warrants (options to buy stock at a specific price) convert their warrants into shares of common stock, providing capital to the company. (A significant source of cash inflow ($3.81M year-to-date) that improved the company's liquidity.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, requiring disclosure and potential mitigation strategies.)

Deferred revenue

Revenue that has been received by a company for goods or services that have not yet been delivered or rendered. It is recorded as a liability until earned. (The company has both current ($873,394) and long-term ($96,729) deferred revenue, indicating future revenue streams tied to unfulfilled obligations.)

Cost of hardware - reserve

A contra-cost account used to reduce the reported cost of hardware, potentially due to returns, obsolescence, or other adjustments. (A negative cost of $277,415 in Q2 2025 and year-to-date suggests a significant adjustment or reversal of previously recognized costs or reserves.)

Year-Over-Year Comparison

Compared to the prior year period, BIO-KEY INTERNATIONAL INC has demonstrated significant improvement in quarterly performance, with total revenues for Q2 2025 increasing by 48.7% to $1.70M, driven by a substantial jump in hardware revenue. The net loss for the quarter also narrowed to $1.17M from $1.67M. However, year-to-date revenue for the first six months of 2025 slightly decreased to $3.30M from $3.32M, primarily due to a sharp decline in license fees. The company's cash position has dramatically improved, reaching $2.28M due to strong proceeds from warrant exercises, a key positive development from the previous reporting period's lower cash balance.

Key Financial Figures

• $0.0001 — registered Common Stock, par value $0.0001 per share BKYI Nasdaq Capital Marke

Filing Documents

• bkyi20250630_10q.htm (10-Q) — 1148KB
• ex_823284.htm (EX-31.1) — 12KB
• ex_823285.htm (EX-31.2) — 12KB
• ex_823286.htm (EX-32.1) — 5KB
• ex_823287.htm (EX-32.2) — 5KB
• 0001437749-25-026549.txt ( ) — 5061KB
• bkyi-20250630.xsd (EX-101.SCH) — 42KB
• bkyi-20250630_cal.xml (EX-101.CAL) — 42KB
• bkyi-20250630_def.xml (EX-101.DEF) — 300KB
• bkyi-20250630_lab.xml (EX-101.LAB) — 263KB
• bkyi-20250630_pre.xml (EX-101.PRE) — 324KB
• bkyi20250630_10q_htm.xml (XML) — 736KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 3

— Financial Statements

Item 1— Financial Statements: Condensed Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) 7 Notes to Condensed Consolidated Financial Statements 9

—Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2—Management's Discussion and Analysis of Financial Condition and Results of Operations. 16

—Quantitative and Qualitative Disclosures about Market Risk

Item 3—Quantitative and Qualitative Disclosures about Market Risk. 23

—Controls and Procedures

Item 4—Controls and Procedures. 23

OTHER INFORMATION

PART II. OTHER INFORMATION 24

—Legal Proceedings

Item 1—Legal Proceedings. 24

—Risk Factors

Item 1A—Risk Factors. 24

—Unregistered Sales of Equity Securities and Use of Proceeds

Item 2—Unregistered Sales of Equity Securities and Use of Proceeds. 24

—Defaults upon Senior Securities

Item 3—Defaults upon Senior Securities. 24

—Mine Safety Disclosures

Item 4—Mine Safety Disclosures. 24

—Other Information

Item 5—Other Information. 24

—Exhibits

Item 6—Exhibits. 24

Signatures

Signatures 25 Table of Contents

-- FINANCIAL INFORMATION

PART I -- FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) ASSETS Cash and cash equivalents $ 2,275,344 $ 437,604 Accounts receivable, net 983,534 718,229 Due from factor 154,769 74,170 Inventory 318,538 378,307 Prepaid expenses and other 303,045 278,648 Total current assets 4,035,230 1,886,958 Equipment and leasehold improvements, net 102,499 140,198 Capitalized contract costs, net 367,125 409,426 Deposits and other assets 7,976 7,976 Operating lease right-of-use assets 60,829 73,372 Investments 5,000,000 5,000,000 Intangible assets, net 942,892 1,097,630 Total non-current assets 6,481,321 6,728,602 TOTAL ASSETS $ 10,516,551 $ 8,615,560 LIABILITIES Accounts payable $ 889,026 $ 818,187 Accrued liabilities 1,170,889 1,278,732 Note payable 447,153 1,525,977 Government loan – BBVA Bank, current portion 125,562 132,731 Deferred revenue, current 873,394 773,267 Operating lease liabilities, current portion 25,886 24,642 Total current liabilities 3,531,910 4,553,536 Deferred revenue, long term 96,729 196,237 Government loan – BBVA Bank – net of current portion - 44,762 Operating lease liabilities, net of current portion 35,735 48,994 Total non-current liabilities 132,464 289,993 TOTAL LIABILITIES 3,664,374 4,843,529 Commitments and Contingencies STOCKHOLDERS' EQUITY Common stock — authorized, 170,000,000 shares; issued and outstanding; 6,848,776 and 3,715,483 of $ .0001 par value at June 30, 2025 and December 31, 2024, respectively 685 372 Additional paid-in capital 137,948,437 133,030,271 Accumulated other comprehensive income 114,898 49,290 Accumulated deficit ( 131,211,843 ) ( 129,307,902 ) TOTAL STOCKHOLDERS' EQUITY 6,852,177 3,772,031 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 10,516,551 $ 8,615,560 See accompanying notes to the condensed consolidate

View Full Filing

View this 10-Q filing on SEC EDGAR